Every month is diabetes awareness month at the Endocrine Society. In the United States, November has been set aside for this purpose, allowing healthcare organizations, advocates, and providers to draw attention to this disease that affects millions of people. I’d like to take this opportunity to recap some of the diabetes-related initiatives at the Endocrine...
New research reveals long-term bone health implications Research presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on...Challenges and Opportunities: Developing New and Improved Treatment Options for Type 1 Diabetes
On behalf of the Endocrine Society’s Early-Career Special Interest Group (SIG), Milay Luis Lam, MD talks with Early-Career SIG steering group member, Manasi Shah, MD, on bringing science to the transplant bedside and discusses her endocrine journey from her native Mumbai, India, to conducting clinical trials in the U.S. You could say that treating people...Why High Testosterone Poses a Silent Threat to Women’s Hearts
The safety profile of zoledronic acid (ZOL), a powerful bisphosphonate widely used for osteoporosis and metastatic bone diseases in cancer patients, has historically been regarded as well-established. Common side effects such as fever, myalgia, and flu-like symptoms are manageable and transient. However, a recent case report in the JCEM Case Reports journal highlights a rare...
